Urge your members of Congress to support continued medical research funding
ASH, the world's
largest professional society concerned with the causes and treatments of blood
disorders, regularly issues press releases highlighting clinical and research
advances announced at the ASH annual meeting and published
in Blood, as well as releases and statements on breaking policy news
affecting the field of hematology.
Need to speak with an expert? Complete our Request An Expert form.
To be added to ASH's press release distribution list, contact Amanda Szabo at email@example.com.
Established in 2012 as short-term support for researchers affected by federal funding shortfalls, the ASH Bridge Grant program is now a permanent society offering. Nine hematologists have received the latest round of awards.
This multinational Phase II study examines brentuximab vedotin (BV) in patients with Hodgkin lymphoma who relapsed after stem cell transplant. The study reports that 13 of 34 (38%) patients who achieved complete remission have remained disease-free for over five years and may be cured. Of those patients, nine received only single-agent BV.
ASH has brought together clinical and laboratory-based scientists, funders, and regulators to share cutting-edge research and tackle key scientific and clinical hurdles in genome editing at the ASH Workshop on Genome Editing, July 14-15 in Washington, DC.
Urge your members of Congress to support continued medical research funding.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology